PMID- 18253152
OWN - NLM
STAT- MEDLINE
DCOM- 20080725
LR  - 20231120
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Linking)
VI  - 16
IP  - 3
DP  - 2008 Mar
TI  - A phase I trial of intratumoral administration of reovirus in patients with 
      histologically confirmed recurrent malignant gliomas.
PG  - 627-32
LID - 10.1038/sj.mt.6300403 [doi]
AB  - Reovirus is an oncolytic virus with activity in in vivo models of malignant 
      gliomas (MGs). The primary aims were to determine the dose-limiting toxicity 
      (DLT) and maximum tolerated dose (MTD) of intratumoral administration of reovirus 
      in patients with recurrent MGs. Response, survival, and time to progression (TTP) 
      were secondary aims. Patients were adults, had Karnofsky Performance score > or = 
      60, received prior radiotherapy with or without chemotherapy, and had up to the 
      third recurrence of MG. Reovirus was administered intratumorally stereotactically 
      at 1 x 10(7), 1 x 10(8), or 1 x 10(9) tissue culture infectious dose 50 (TCID50) 
      in a volume of 0.9 ml. Twelve patients were treated at three dose levels (3, 6, 
      and 3 patients, respectively). Seven were men, median Karnofsky Performance score 
      was 80, and median age was 53.5 years. There were no grade III or IV adverse 
      events (AEs) definitely or probably related to treatment. Ten patients had tumor 
      progression, one had stabilization, and one was not evaluable for response. 
      Median survival was 21 weeks (range, 6-234), and one is alive 54 months after 
      treatment. Median TTP was 4.3 weeks (range, 2.6-39). An MTD was not reached. The 
      intratumoral administration of the genetically unmodified reovirus was well 
      tolerated using these doses and schedule, in patients with recurrent MG.
FAU - Forsyth, Peter
AU  - Forsyth P
AD  - Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada. 
      pforsyth@ucalgary.ca
FAU - Roldan, Gloria
AU  - Roldan G
FAU - George, David
AU  - George D
FAU - Wallace, Carla
AU  - Wallace C
FAU - Palmer, Cheryl Ann
AU  - Palmer CA
FAU - Morris, Don
AU  - Morris D
FAU - Cairncross, Gregory
AU  - Cairncross G
FAU - Matthews, Maureen Vallee
AU  - Matthews MV
FAU - Markert, James
AU  - Markert J
FAU - Gillespie, Yancey
AU  - Gillespie Y
FAU - Coffey, Matt
AU  - Coffey M
FAU - Thompson, Brad
AU  - Thompson B
FAU - Hamilton, Mark
AU  - Hamilton M
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080205
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Adult
MH  - Antibodies, Viral/blood
MH  - Brain Neoplasms/pathology/*therapy
MH  - Female
MH  - Glioma/pathology/*therapy
MH  - Headache/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Weakness/etiology
MH  - Neoplasm Recurrence, Local
MH  - Oncolytic Virotherapy/adverse effects/*methods
MH  - Oncolytic Viruses/immunology/physiology
MH  - Reoviridae/immunology/*physiology
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2008/02/07 09:00
MHDA- 2008/07/26 09:00
CRDT- 2008/02/07 09:00
PHST- 2008/02/07 09:00 [pubmed]
PHST- 2008/07/26 09:00 [medline]
PHST- 2008/02/07 09:00 [entrez]
AID - S1525-0016(16)31438-1 [pii]
AID - 10.1038/sj.mt.6300403 [doi]
PST - ppublish
SO  - Mol Ther. 2008 Mar;16(3):627-32. doi: 10.1038/sj.mt.6300403. Epub 2008 Feb 5.